Berwick, among the nation’s leading authorities on healthcare quality improvement, is certainly president and ceo of the Institute for Health care Improvement located in Cambridge, Mass. Dr. Berwick can be Clinical Professor of Pediatrics and HEALTHCARE Plan at the Harvard Medical College and professor of Health Policy and Management at the Harvard School of Public Health. He’s a 2005 recipient of the ASHP Panel of Directors Award of Honor..Results were reported on a 17-year-old patient who was identified as having DDD with normal renal function but significant proteinuria . To date, the patient offers been treated with Soliris for 16 weeks. The reported results indicate that Soliris treatment was connected with a significant increase in serum albumin and proteins, in addition to a decrease in both urine protein/creatinine ratio and 24 hour protein. His bloodstream and creatinine pressure remain normal. The investigators reported no drug-related undesireable effects while on Soliris over the 16-month treatment period and figured Soliris may be an important therapeutic option for sufferers with DDD. ‘Membrano Proliferative Glomerulonephritis: 3 Case Reports,’ S. Hartl. Researchers record on three individuals with MPGN, two with MPGN type I and one with MPGN type II or DDD, with different clinical courses and biopsy outcomes.